|The deregulations in the recent years and the adoption of ICH standards in Japan have resulted not only in an increased number of medicinal products registered in Japan but also in the developments unprecedented before in terms of speed and procedure. Certain critically important categories of therapeutic agents - in CNS field, pain control, inflammation, lipid control - attract the attention of the potential overseas product developers due to the large capacity of the Japanese market.|
A sample represented by a Memo on a tentative Case Study is
available for download here. The format and the contents of the
actual Case Study Reports are highly customizable.
Click to download a Sample Case Study Memo | Inquire for more info...